Praxis Precision Medicines to Present at Upcoming Investor Conferences
BOSTON, March 03, 2023 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences:
- 43rd Annual TD Cowen Health Care Conference
- Orphan epilepsies panel on Monday, March 6, 2023 at 12:50 p.m. ET
- Orphan epilepsies panel on Monday, March 6, 2023 at 12:50 p.m. ET
- Needham Neuroscience Forum
- Fireside chat on Wednesday, March 15, 2023 at 2:00 p.m. ET
The events will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at . Replays of the webcasts will be available on Praxis’ website for at least 30 days following the events.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit and follow us on and .
Investor Contact Alex Kane Praxis Precision Medicines 617-300-8481 Media Contact Ian Stone Canale Communications 619-849-5388
